TG Therapeutics faces earnings test after profit disappointment

TG Therapeutics is expected to report Q3 EPS of $0.37 and revenue of $245.5 million before Monday’s open; the EPS forecast is up from $0.05 in Q2, while revenue is about 2% above Q2’s $240.3 million. Investors will assess BRIUMVI sales against the company’s roughly $950 million full-year global revenue guidance and look for evidence that operating leverage can support sustained profitability after the prior-quarter earnings miss. Analysts’ EPS estimates have fallen 21% over 60 days, while the consensus rating remains Strong Buy with a $69.71 mean price target versus a $57.98 share price.

Analysis

The key earnings test is conversion, not demand: with revenue growth slowing sequentially, a large EPS step-up would need to come from expense control, mix, or other operating leverage rather than simply more sales. If commercial and clinical spending remains elevated, investors may conclude that the current earnings run rate is not durable—even if BRIUMVI uptake remains healthy. The recent estimate cuts may have lowered the bar, but the concentration of bullish ratings and a valuation that assumes substantial future earnings growth leave room for a sharp reaction to cautious guidance.

Over the next 1–3 months, monitor BRIUMVI prescription and payer-access trends alongside operating expenses and cash generation. Competitors including Ocrevus and Kesimpta can limit pricing power or raise the cost of maintaining share; the relevant signal is whether TG can grow without proportionate commercial spending. The azer-cel program is longer-dated optionality, not a near-term offset to weak earnings conversion. Over 6–18 months, sustained BRIUMVI growth with improving expense leverage would support the transition to a profitable commercial business; persistent spending growth or weaker uptake would challenge that thesis. The setup is asymmetric around the report: a beat alone may not suffice if profitability guidance disappoints.

Key Decisions for Investors

• Avoid initiating a large directional position before the report; the event risk is high and the valuation leaves limited room for an earnings-quality miss.
• After the release, consider adding to TGTX only if management demonstrates improving expense leverage and maintains credible BRIUMVI growth guidance. Treat revenue strength without a clear profitability path as insufficient confirmation.
• If earnings conversion or forward guidance disappoints, consider a defined-risk bearish position rather than assuming the selloff will be brief; reassess once management provides evidence that spending is stabilizing.
• Track subsequent BRIUMVI uptake and payer access, operating expenses, and cash generation. A slowdown in demand or continued expense growth would falsify the improving-profitability thesis; sustained growth with better expense leverage would weaken the bearish case.